Yongkun Sun - Concepedia

Author

Yongkun Sun

Chinese Academy of Medical Sciences & Peking Union Medical College ORCID

Also Known As

Sun, Yongkun, Sun,Yan, W. Zhang, Y K Sun, Y Sun, Y. Sun, Y.S. Sun, Yong-Kun Sun, Yong-kun Sun, YongFu Sun

139

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College Sun Yat-sen University Peking University Cancer Hospital Peking University Sun Yat-sen University Cancer Center

About

Yongkun Sun is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	135
2	Health Sciences	3	3	56
3	Cell Biology	2	2	37
4	Biochemistry	1	1	21
5	Hepatology	1	1	22

Yongkun Sun

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors Yongkun Sun, Wei Niu, Feng Du, Journal of Hematology & Oncology	2016	421
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma Yihebali Chi, Zhiwei Fang, Xiaonan Hong, Clinical Cancer Research	2018	322
PAMAM Nanoparticles Promote Acute Lung Injury by Inducing Autophagic Cell Death through the Akt-TSC2-mTOR Signaling Pathway Caifeng Li, Haizhou Liu, Yongkun Sun, Journal of Molecular Cell Biology	2009	256
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Yongkun Sun, Feng Du, Ming Gao, Thyroid	2018	109
Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: Overall design and results from a multicenter retrospective epidemiologic survey Jufang Shi, Le Wang, Jian‐Chao Ran, Cancer	2021	103
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China Yuelu Zhu, Yongkun Sun, Shangying Hu, BMC Gastroenterology	2017	67
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703) Yihebali Chi, Yongqian Shu, Yi Ba, The Oncologist	2021	61
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study) Yongkun Sun, Aiping Zhou, Wen Zhang, Hepatology International	2021	55
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients Wen Zhang, Caifeng Gong, Xuenan Peng, Clinical Cancer Research	2022	55
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis Jun Zhou, Yongkun Sun, Wen Zhang, Hepatology	2022	49

Page 1